EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD+ AML WHO RECEIVED CONTINUATION THERAPY

EHA HIGHLIGHTS 2024 – LEUKEMIA ROUNDTABLE DISCUSSION: EFFICACY IN NEWLY DIAGNOSED PATIENTS WITH FLT3-ITD+ AML WHO RECEIVED CONTINUATION THERAPY

EHA Highlights 2024 Roundtable Discussions
Pre-Video Survey
Post-Video Survey
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Panelists

Dr. Julie Bergeron
Dr. Aniket Bankar

This program has been made possible through unrestricted support from Astellas.

Studies/trials discussed:

  • Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial
Tagged